Annovis Bio, Inc.

Annovis Bio, Inc.

0.75
USD
-0.18
(-19.02%)
-1.80EPS
79.25MMarket Cap
Apr 06Next Earn

Total Valuation

USD

As of June 30, 2026, Annovis Bio, Inc. carries a market capitalization of 79.25M, placing it among publicly traded companies globally. Its enterprise value stands at 60.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap79.25M
Enterprise Value60.52M

Important Dates

Annovis Bio, Inc.'s next confirmed earnings release is scheduled for April 6, 2027.

Earnings Date4/6/2027

Share Statistics

As of June 30, 2026, Annovis Bio, Inc. has 42.61M shares outstanding.

Shares Outstanding42.61M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio-18.63
P/TBV Ratio-18.63
P/FCF Ratio-1.18
P/OCF Ratio-1.18

Financial Position

As of June 30, 2026, Annovis Bio, Inc. maintains a current ratio of 3.47, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

Current Ratio3.47
Quick Ratio2.95

Financial Efficiency

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -227.74, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-227.74
Employee Count8.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Annovis Bio, Inc.'s stock has declined approximately 67.95% over the past 52 weeks. The 50-day moving average sits at 1.09, while the 200-day moving average is 1.80.

52-Week Price Change-67.95%
50-Day Moving Average1.09
200-Day Moving Average1.80

Income Statement

USD

Over the twelve months ended June 30, 2026, Annovis Bio, Inc. generated - - in revenue and converted that into -49.52M in net income, yielding earnings per share of -1.80. EBITDA reached -49.53M, while operating income came in at -49.53M.

Operating Income-49.53M
Pretax Income-49.52M
Net Income-49.52M
EBITDA-49.53M
EBIT-49.53M
Earnings Per Share (EPS)-1.80

Balance Sheet

USD

These figures are as of June 30, 2026. Total book value stands at -4.25M, with working capital of 15.68M providing operational flexibility.

Cash & Cash Equivalents18.73M
Net Debt-18.73M
Equity (Book Value)-4.25M
Book Value Per Share-0.10
Working Capital15.68M

Cash Flow

USD

Annovis Bio, Inc. produced -43.34M in operating cash flow over the twelve months ended June 30, 2026.

Operating Cash Flow-43.34M
Free Cash Flow-43.34M
FCF Per Share-1.58

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -84.84: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -56.71, meaning Annovis Bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-56.71
FCF Yield-84.84

Scores

As of June 30, 2026, Annovis Bio, Inc. has an Altman Z-Score of -17.21, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-17.21